Spravato® (esketamine) is the first prescription nasal spray, taken with an oral antidepressant, which is FDA-approved for:
Adults with treatment-resistant depression. Treatment-resistant depression (TRD) presents as depression in patients struggling with major depressive disorder who have not responded adequately to two or more antidepressants.
On treatment days, patients will administer Spravato® nasal spray themselves under the guidance and supervision of a physician at our PATH Counseling Center.
After administering Spravato®, there is an observation period of approximately two hours, during which patients relax and rest comfortably in the privacy of individual treatment rooms designed to provide comfort and relaxation during that time. while being monitored for rare potential side effects.
Due to the rare, though potential, side effects which may occur, primarily drowsiness or a mild elevation in blood pressure in the early part of treatment, individuals are asked to arrange transportation after each treatment and not to drive themselves. Our office can assist with arranging Veyo or other transportation services.
Side effects may last up to 24 hours, resolving completely with restful sleep should they occur, but most patients experience little or no fatigue upon leaving our offices.
LEARN MORE You can learn more about Spravato® therapy at Spravato.com. where you will also find a list of commonly asked questions many people have about Spravato®. You should also speak with your health care provider.
REQUEST AN ASSESSMENT
If you are interested in an assessment for Spravato® therapy, your community provider can provide a referral. You can also contact our Front Desk Team at (860) 450-0151
Willimantic Counseling Center
842 Main Street, Willimantic, CT 06226 Call us today at (860) 450-0151